Log in to your Inderes Free account to see all free content on this page.
Cereno Scientific
6.70 SEK
+1.98 %
Less than 1K followers
CRNO B
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+1.98 %
-0.67 %
-4.15 %
+2.68 %
-27.84 %
+34.11 %
+235.00 %
+262.16 %
+11.46 %
Cereno Scientific is a biotechnology company. The company specializes in drug development for common and rare cardiovascular diseases. The lead drug candidate is being developed for the treatment of the rare disease pulmonary arterial hypertension, as well as for thrombotic indications. In particular, epigenetic modulation is used to develop treatments for needy patients with cardiovascular diseases. Cereno Scientific's headquarters are located in Mölndal.
Read moreMarket cap
2.09B SEK
Turnover
2.67M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
27.2.
2026
Annual report '25
29.4.
2026
Interim report Q1'26
17.6.
2026
General meeting '26
All
Webcasts
Press releases
3rd party
ShowingAll content types
Cereno Scientific broadens development focus for CS014 to pulmonary hypertension associated with interstitial lung disease
Cereno Scientific Provides Update on Expanded Access Program for CS1 - initial learnings expected in Q1 2026
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio